KOSDAQElectronic Components290660

Dynamic solution

₩1,064▲ 1.24%2026-11-18 close
Market Cap
₩45.6B
Turnover
₩200M
Volume
220K
Shares out.
42.8M
PER
—
PBR
—
EPS
-₩290
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Core Business Shrinks as BCI and Materials Take Shape

Revenue has declined for two straight years since its 2023 peak and losses have continued from 2022 through 2025, while the company reorganizes around BCI and a silica slurry plant in Ulsan.

  1. 1

    2025 revenue was KRW 16.1 billion, far below KRW 26.6 billion in 2023, and rehabilitation medical device segment sales also fell from the prior year.

  2. 2

    The 2025 operating loss was KRW 2.9 billion and the net loss attributable to controlling shareholders widened to KRW 12.3 billion, while media reports pointed to KRW 8.9 billion in financing costs as a burden.

  3. 3

    Net losses attributable to controlling shareholders continued for three straight quarters from the first quarter through the third quarter of 2026, and the four quarters from the fourth quarter of 2025 through the third quarter of 2026 total a KRW 11.9 billion net loss.

  4. 4

    The KRW 20 billion ninth convertible bond decided in March 2026 carries a conversion price of KRW 1,347 and equals about 19.07% of shares outstanding at issuance, a dilution factor.

  5. 5

    The Ulsan silica slurry plant targets construction completion at the end of February 2027, with mass production planned for the same year, and is the next milestone to watch.

02

Business structure

Dynamic Solution develops and sells rehabilitation medical devices for patients with neurological and musculoskeletal conditions such as stroke, and also provides long-term care services.

In 2025, sales in the rehabilitation medical device segment were KRW 10.6 billion versus KRW 11.6 billion a year earlier, and long-term care service sales were KRW 5.4 billion, down 3.0% year on year.

Within rehabilitation devices, product sales edged up to KRW 8.1 billion while merchandise sales fell more than 45% to KRW 1.5 billion.

The company changed its name from Neofect to Dynamic Solution in March 2026 and in April 2026 reorganized its business into three pillars: rehabilitation robots, industrial robots and materials.

Rehabilitation robots are the existing base business, industrial robots are an expansion business, and materials are positioned as part of the robot value chain.

Its core technology is the brain-computer interface (BCI), which reads brain signals to drive robotic movement, built on technology transfer and joint R&D with the Electronics and Telecommunications Research Institute (ETRI).

In materials, the company plans to produce high-purity silica slurry used in semiconductors and optical cables in Ulsan, and is tuning formulations to the processes of prospective customers and evaluation partners including LG Chem and Doosan Electronics.

Overseas, the company treats Vietnam as its Asian hub and has discussed supply and distribution with hospitals and distributors, while its K-beauty brand Kokkok Garden grew sales on TikTok Shop in Vietnam.

The BCI market has been led by foreign players such as Neuralink, Kernel, Blackrock Microsystems and Emotiv, and the company is challenging that position together with domestic BCI partners. Overall results still depend largely on the sales scale of the core rehabilitation device business.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩900M-₩1.3B−152.1%
2025Q4₩4.4B-₩700M−15.2%
2026Q1₩3.1B-₩3.1B−98.2%
2026Q2₩4.2B-₩1B−22.8%
2026Q3₩3.2B-₩3.1B−99.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩26.2B-₩7.5B-₩9.6B−28.8%−148.4%426.1%
2023₩26.6B-₩1.8B-₩5B−6.7%−17.2%128.0%
2024₩21.1B-₩2.4B-₩1B−11.4%−2.4%89.2%
2025₩16.1B-₩2.9B-₩12.3B−18.1%−23.1%46.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 26.2 billion in 2022 to a peak of KRW 26.6 billion in 2023 (up 1.6% year on year), then fell to KRW 21.1 billion in 2024 (down 20.7%) and KRW 16.1 billion in 2025 (down 24.0%), a two-year decline.

The operating loss narrowed from KRW 7.54 billion in 2022 to KRW 1.78 billion in 2023, then widened to KRW 2.41 billion in 2024 and KRW 2.9 billion in 2025, and the company has recorded losses for four consecutive years from 2022 through 2025.

The operating margin moved from -28.8% in 2022 to -6.7% in 2023, then -11.4% in 2024 and -18.1% in 2025, so the loss rate reversed after sales began to shrink.

The net loss attributable to controlling shareholders fell from KRW 9.62 billion in 2022 to KRW 4.96 billion in 2023 and KRW 951 million in 2024, then widened to KRW 12.3 billion in 2025.

Total net loss including non-controlling interests was KRW 1.47 billion in 2024, larger than the controlling-shareholder figure of KRW 951 million for that year, and KRW 12.3 billion in 2025. Media reports pointed to financing costs of KRW 8.9 billion in 2025, up 81.5% year on year, as a driver of the widening loss.

Within that figure, interest expense was KRW 3.8 billion and derivative valuation losses rose to KRW 2.7 billion from KRW 100 million a year earlier, and one analysis described the derivative loss as an accounting loss without direct cash outflow.

Reports also cited a loss of more than KRW 1.4 billion from discontinued operations in 2025. The debt ratio fell from 426.1% in 2022 to 128.0% in 2023, 89.2% in 2024 and 46.3% in 2025, and operating cash flow losses narrowed from KRW 5.7 billion in 2022 to KRW 233 million in 2025.

Quarterly revenue went from KRW 881 million in the third quarter of 2025 to KRW 4.45 billion in the fourth quarter (up 404.6% from the prior quarter), then KRW 3.13 billion, KRW 4.17 billion and KRW 3.15 billion in the first three quarters of 2026, the last up 257.5% year on year.

Operating losses have run for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, and the third-quarter 2026 operating loss of KRW 3.12 billion was larger than a year earlier.

In the fourth quarter of 2025, the company posted a KRW 4.94 billion profit attributable to controlling shareholders despite a KRW 676 million operating loss, while the first three quarters of 2026 recorded net losses of KRW 5.85 billion, KRW 4.83 billion and KRW 6.15 billion.

05

Industry analysis

The core of the materials business is high-purity silica slurry used in advanced industries such as semiconductors and optical cables, and the company says it aims to build a domestic supply base for a material previously imported almost entirely.

On the customer side, the company says it is prioritizing evaluation and mass-production preparation with large corporate customers including LG Chem and Doosan Electronics.

The company is also reviewing in-house development of alumina-based heat-dissipation products and plans to gauge demand through sales cooperation with technology partners.

The BCI field has been led by foreign companies, and in June 2026 the Korea BCI Association was launched, indicating that a domestic ecosystem is taking shape.

At the national level, the K-Moonshot program overseen by the Ministry of Science and ICT plans to invest KRW 600 billion in research funds from 2026 through 2030, and the company has set up a dedicated BCI team to take part.

In humanoid and industrial robots, cooperation with Chinese robot makers that supply hardware while the company handles software is expanding.

In rehabilitation devices, the challenge is widening hospital and distribution channels at home and abroad, and the company is expanding distribution cooperation in Asian markets including Vietnam.

A simple comparison with listed electronic component companies has limited meaning because the business mix and scale differ, and the industry outlook for the company depends on how quickly it wins customers in its two newer areas, materials and BCI.

06

Outlook

The Ulsan plant targets construction completion at the end of February 2027, with mass production planned for the same year. Construction was originally scheduled to begin in July 2026 but was delayed by licensing procedures, and the groundbreaking ceremony was held on September 29, 2026.

The company is prioritizing customer evaluation and mass-production preparation for silica slurry, and aims to start supplying large corporate customers in tandem with completion of the new plant.

On the BCI side, the company signed an MOU with the Chinese humanoid robot maker MagicLab Robot Technology on October 20, 2026, covering domestic production of robots and domestic distribution.

It plans to bring the Magicbot Z1 into Korea, complete local certification and registration, and begin BCI consortium cooperation and full-scale sales from the first quarter of 2027.

The BCI robotic hand glove was first shown at WRC 2026 in August 2026, and the company plans to develop medical and rehabilitation products first before expanding to industrial and general-purpose robotic hands.

Preparations for a second-phase clinical trial running in Korea and Germany simultaneously began in April 2026. At CES 2027 in Las Vegas in early 2027, the company plans to show a remote tactile robot glove that conveys touch and temperature back to the user.

The company also said it is preparing an acquisition of a firm with commercialized robotic hand technology for its humanoid business, but the target and timing have not been set. With many key milestones falling in 2027, the effects of the new businesses are not yet reflected in disclosed 2026 results.

07

Valuation

PER
—
PBR
—
ROE
-31.3%
EPS
-₩290
BPS
—
Dividend per share
₩0

Because the most recent four quarters combined show a net loss, no earnings-based multiple is calculated at present.

Compared with the controlling-shareholder equity of KRW 53.3 billion at the end of 2025, the market capitalization sits in a range below book value, so the share price is trading below net asset value on the balance sheet.

A share price below net asset value is read alongside the possibility of a rising share count from convertible bond conversion. Dividend returns are effectively absent, so valuation rests on the balance between expectations for new business execution and financial burdens.

Over several years, the debt ratio fell from 426.1% in 2022 to 46.3% in 2025, and operating cash flow losses narrowed from KRW 5.7 billion to KRW 233 million, a directional improvement on the financial side.

Media interpretations attributed the share price rise in March 2026 to expectations for technology competitiveness, which suggests that the stock has reacted more to business announcements than to reported earnings. Trading in common shares was suspended from June 5, 2026 as part of a share consolidation process.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

BCI Technology and National R&D Role

The company signed a BCI technology commercialization agreement with WiBrain on March 10, 2026, and has set up a dedicated team to take part in the K-Moonshot project, which carries KRW 600 billion in funding from 2026 through 2030.

It says more than 40 national R&D projects completed since its 2010 founding were used in developing the BCI robotic hand glove. It also acquired core intellectual property for the X-HAND tactile robotic hand technology from ETRI. Whether these research results turn into products and clinical use is the test of this advantage.

Building Production Base in Materials

The Ulsan silica slurry plant targets construction completion at the end of February 2027 and mass production in the same year, with the company stating that it will supply advanced-industry materials such as those for semiconductors and optical cables domestically.

In April 2026 the company also secured exclusive production and sales rights for inorganic chemical materials from Giant Chemical, a magnesium silicate maker, broadening its materials lineup.

The company expects that if evaluations by large corporate customers convert into supply contracts, the materials business could widen its sales base.

Improving Financial Structure

The debt ratio fell from 426.1% in 2022 to 46.3% in 2025, and operating cash flow losses narrowed from KRW 5.7 billion in 2022 to KRW 233 million in 2025. In the fourth quarter of 2025 the company posted a KRW 4.94 billion profit attributable to controlling shareholders even with a KRW 676 million operating loss. Since that quarter, quarterly revenue has stayed within a KRW 3.1 billion to KRW 4.2 billion range.

09

Bear factors

Continued Decline in Core Sales

Revenue fell from the KRW 26.6 billion peak in 2023 to KRW 16.1 billion in 2025, and rehabilitation device segment sales dropped from KRW 11.6 billion to KRW 10.6 billion over the same period. Merchandise sales fell more than 45% to KRW 1.5 billion, making recovery in the core segment a key challenge.

Long-term care service sales also declined 3.0% year on year. Reported results do not yet show new businesses filling the gap left by the core decline.

Financing Burden and Persistent Losses

Financing costs reached KRW 8.9 billion in 2025, up 81.5% year on year, and one analysis said that equaled 55.6% of revenue. Operating losses have run for four consecutive years from 2022 through 2025 and for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

Losses attributable to controlling shareholders in the four quarters through the third quarter of 2026 total KRW 11.9 billion. Media reports said accumulated deficit grew to KRW 71.1 billion at the end of 2025.

Convertible Bond Dilution and Shifting Use of Funds

The KRW 20 billion ninth convertible bond decided in March 2026 equals 19.07% of shares outstanding at issuance if converted.

Its stated use of funds moved from new-business operating capital to acquiring securities of other companies and then to general funds, and was used to buy a commercial building in Songpa-gu, Seoul for KRW 10.8 billion. Media reports described a gap between expectations for new business and the actual use of funds.

10

Risk factors

Execution Risk

The Ulsan plant was originally planned to start construction in July 2026, but licensing delays pushed the groundbreaking to September 2026. Completion is targeted for the end of February 2027, and revenue still requires customer evaluation and mass-production preparation after completion.

Robot products still need domestic certification and registration. A delay in one milestone could push back revenue timing for the follow-on businesses.

Dilution and Financing Risk

The company raised about KRW 13.5 billion in 2025 through a rights offering and convertible bond issuance, and in March 2026 it decided on another KRW 20 billion convertible bond. Conversion would increase the share count and dilute existing shareholders, and derivative valuation gains and losses add volatility.

Trading in common shares was suspended from June 5, 2026 for a share consolidation. Further external financing could increase dilution pressure.

Governance and Use-of-Funds Risk

After the largest shareholder changed in August 2025, the company renamed itself and presented several blueprints for new businesses. However, the stated purpose of its convertible bond financing changed several times and the proceeds were ultimately used to buy real estate.

Repeated gaps between announced new-business intentions and actual fund use could weigh on confidence in the business. A company representative had said there were no additional external financing plans at the time.

11

What to watch next

  1. Early 2027

    Check whether the remote tactile robot glove slated for CES 2027 comes with a commercialization timeline and partners. Whether the technology demonstration leads to business contracts is the next signal for the BCI business.

  2. Q1 2027

    Check whether domestic certification and registration of the Magicbot Z1 are completed and BCI consortium cooperation and sales begin. The key point is whether robot-related revenue appears in disclosed results from the first quarter of 2027 onward.

  3. End of February 2027

    Check whether the Ulsan silica slurry plant completes construction as targeted and whether mass production begins in the same year. A delay in completion would also push back the timing of materials revenue.

  4. Late March 2027

    Check the filing and contents of the 2026 annual report. Annual operating margin, financing costs, derivative valuation gains and losses, and the outstanding convertible bond balance are the key checkpoints in the next regular report.

  5. Mid-May 2027

    Check revenue scale, operating loss size and the net loss attributable to controlling shareholders in the first-quarter 2027 report. Whether the streak of consecutive losses through the third quarter of 2026 is broken is the point to watch.

12

Overall view

Dynamic Solution is in a phase of reorganizing around materials and BCI while its core rehabilitation device sales have fallen for two straight years since the 2023 peak and operating losses have continued since 2022.

On the financial side, the debt ratio fell from 426.1% in 2022 to 46.3% in 2025 and operating cash flow losses narrowed, but financing costs of KRW 8.9 billion in 2025 and net losses attributable to controlling shareholders from the first through third quarters of 2026 remain burdens.

On the new-business side, the national BCI project, the MOU with a Chinese robot maker and the Ulsan materials plant are active items, but the scale converting into revenue in disclosed results is not yet clear.

The Ulsan plant targets completion at the end of February 2027 and mass production in the same year, while robot products are scheduled to reach full-scale sales from the first quarter of 2027.

On the funding side, the dilution potential of the KRW 20 billion convertible bond and the shift in its use of funds remain questions for confidence in the business.

The next checkpoints are the operating margin and financing costs in the 2026 annual report, and whether the Ulsan plant completes construction and starts mass production in 2027. This report does not offer a buy or sell opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. newstomato.com
  2. view.asiae.co.kr
  3. sedaily.com
  4. thevc.kr
  5. bloter.net
  6. dealsite.co.kr
  7. magazine.hankyung.com
  8. businessreport.kr
  9. bloter.net
  10. thetracker.co.kr
  11. neofect.com
  12. view.asiae.co.kr
  13. dynamicsolution.co.kr
  14. view.asiae.co.kr
  15. view.asiae.co.kr
  16. digitaltoday.co.kr
  17. digitaltoday.co.kr
  18. irobotnews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis